Engasertib

N/A

Report date: 2026/01/16 15:31:47
NME

Base Information

Drug NameEngasertib
Drug Alias NameVAD044 L-Tartrate gelatin capsulesVAD-044ALM-301
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene proteins c-akt inhibitors
TargetsProto-oncogene proteins c-akt
Therapy Area/IndicationsTelangiectasia, Hereditary Hemorrhagic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVaderis Therapeutics AG
China Registration ClassN/A

Develop Information

Active CompaniesVaderis Therapeutics AG
Inactive CompaniesN/A
Active IndicationsTelangiectasia, Hereditary Hemorrhagic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A